Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00088621 · ClinicalTrials.gov registry record · Phase 2
A Study to Test the Safety and Tolerability of a New Medication in the Treatment of Schizophrenia
A Phase 2 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
NCT00088621 is a Phase 2 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 61 participants.
The verdict
NCT00088621, a Phase 2 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
Study Summary
A 1-year outpatient study to test the safety and tolerability of a new medication in the treatment of schizophrenia
Interventions
- DRUG Lurasidone 80mg tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2004-07 |
| Est. Completion | 2005-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00088621
The ClinicalTrials.gov registry entry for NCT00088621 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lurasidone 80mg tablet is the first listed.
NCT00088621 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00088621 about?
NCT00088621 is a clinical study titled "A Study to Test the Safety and Tolerability of a New Medication in the Treatment of Schizophrenia". A 1-year outpatient study to test the safety and tolerability of a new medication in the treatment of schizophrenia
What is the current status of trial NCT00088621?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2004-07. Estimated completion is 2005-10.
What interventions are being tested in trial NCT00088621?
The interventions under investigation include: Lurasidone 80mg tablet (DRUG).
Who is sponsoring clinical trial NCT00088621?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.